Focal Mass Drug Administration (fMDA)

Phase 3

Allergy Therapeutics plc (AGY.L)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

AGY.LPhase 3$6M

Focal Mass Drug Administration (fMDA) Phase 3 Est. Readout

Focal Mass Drug Administration (fMDA)• Plasmodium Vivax Malaria7,530

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Plasmodium Vivax Malaria

View Full Landscape

Drug Information

Target Indication

Plasmodium Vivax Malaria

Clinical Trial

NCT05690841

Last updated: 9/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AGY.L

Allergy Therapeutics plc

Pharmaceutical Preparations•Europe•AIM

Related Pipeline

SUBLIVAC FIX BirchPhase 3

Allergic Rhinitis

SUBLIVAC® Grasses treatmentPhase 3

Rhinitis, Allergic, Seasonal

Anti-HIV Immune Serum Globulin (Human)Phase 3

HIV Infections

Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)Phase 3

Eosinophilic Gastrointestinal Disorders (EGIDs)

PURETHAL Mites 50,000 AUeq/mlPhase 3

House Dust Mite Allergy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts